No Data
No Data
Conduit Pharmaceuticals Received Written Notification From The Panel Confirming It Has Granted The Co An Extension To Regain Compliance On Or Before March 12, 2025
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
Conduit Progresses Phase II of Its AI Initiative With Sarborg
Express News | Conduit Pharmaceuticals Files for Offering of up to $17.8 Mln of Shares of Common Stock - SEC Filing
Express News | Conduit Pharmaceuticals: Study to Accelerate Development of Azd1656 for Autoimmune Disorders, Focus on Systemic Lupus Erythematosus, Lupus Nephritis
Trailside22 : well done dr.
CloverJen : thank you
Common and basic : thanks!
MarshmallowQ : Friends, what will you buy tomorrow?
MarshmallowQ : Anyone in $Aclarion (ACON.US)$ ?
View more comments...